Printer Friendly

POSSIS MEDICAL FILES INVESTIGATIONAL DEVICE EXEMPTION APPLICATION

 POSSIS MEDICAL FILES INVESTIGATIONAL DEVICE EXEMPTION APPLICATION
 MINNEAPOLIS, March 30 /PRNewswire/ -- Possis Corporation (NASDAQ: POSS) announced today that Possis Medical, Inc. (PMI), its wholly owned subsidiary, has filed an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) for its Perma-Seal(TM) A-V Graft Fistula. PMI is currently preparing to begin human clinical trials in the United States following IDE approval.
 The IDE application is a major step toward PMI's goal of entering an estimated $25 million/year A-V graft business, thus helping position the company as an emerging provider of synthetic peripheral grafts and a pioneer in providing synthetic coronary grafts. PMI's Perma-Flow(R) Coronary Graft received IDE approval earlier and is expected to enter human clinical trials within the next few weeks.
 Perma-Seal is a unique, isodiametric (straight) A-V graft fistula using PMI's proprietary graft material, a composite of porous, silicone rubber and polyester thread. PMI believes Perma-Seal can offer important product advantages for patients requiring long-term vascular access for kidney dialysis. The graft has excellent anti-kink and anti- crush properties, but most importantly, when compared to conventional synthetic A-V grafts, Perma-Seal offers self-sealing properties which can help seal off needle hole puncture sites, thereby enhancing the possibility for early graft cannulation following implant and reducing the chances for excessive bleeding and tissue ingrowth following cannulation.
 -0- 3/30/92
 /CONTACT: Robert G. Dutcher of Possis Medical, 612-550-1010/
 (POSS) CO: Possis Corporation; Possis Medical, Inc. ST: Minnesota IN: MTC SU:


DS -- MN004 -- 2751 03/30/92 09:42 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1992
Words:256
Previous Article:WALGREEN CO. REPORTS RECORD SALES, EARNINGS FOR SECOND QUARTER, FIRST HALF 1992
Next Article:PENN CENTRAL REORGANIZES ITS WIRE AND CABLE OPERATIONS
Topics:


Related Articles
POSSIS MEDICAL RECEIVES FDA APPROVAL FOR IDE APPLICATION
POSSIS MEDICAL FILES INVESTIGATIONAL DEVICE EXEMPTION APPLICATION
POSSIS MEDICAL BEGINS HUMAN CLINICAL IMPLANTS OF PERMA-FLOW(R)
POSSIS MEDICAL BEGINS U.S. HUMAN CLINICAL STUDY OF ITS PERMA-SEAL DIALYSIS ACCESS GRAFT
POSSIS MEDICAL EXPANDS ANGIOJET CLINICAL STUDY TO INCLUDE A-V ACCESS GRAFTS
POSSIS MEDICAL, INC. APPLIES TO FDA FOR COMMENCEMENT OF ANGIOJET(TM) CORONARY THROMBECTOMY STUDY
POSSIS MEDICAL FILES 510(k) AND IDE APPLICATIONS AND RECEIVES SECOND U.S. PATENT FOR ANGIOJET RAPID THROMBECTOMY SYSTEM
BAXTER AND POSSIS ENTER INTO ALLIANCE FOR DISTRIBUTION OF POSSIS SYNTHETIC CORONARY ARTERY BYPASS GRAFT
Possis Medical, Inc. Seeks FDA Approval to Begin Stroke Clinical Trial with the AngioJet System
FDA Approves Possis Medical AngioJet(R) Clinical Trial for Stroke Treatment.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters